Back to top
more

CytomX Therapeutics, Inc. (CTMX)

(Delayed Data from NSDQ)

$7.07 USD

7.07
454,740

+0.08 (1.14%)

Updated Aug 12, 2020 04:00 PM ET

After-Market: $7.07 0.00 (0.00%) 7:57 PM ET

4-Sell of 5       4  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value A Growth A Momentum A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

CytomX Therapeutics (CTMX) Earnings Expected to Grow: Should You Buy?

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CytomX Therapeutics (CTMX) Moves to Buy: Rationale Behind the Upgrade

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is CytomX Therapeutics (CTMX) Stock Outpacing Its Medical Peers This Year?

Is (CTMX) Outperforming Other Medical Stocks This Year?

Benjamin Rains

Find Strong Stocks Ahead of Q2 Earnings Season with this First Profit Screener

We used our 'First Profit' stock screener to help investors find strong stocks that might be worth looking at in preparation for Q2 earnings season...

Zacks Equity Research

Is CytomX Therapeutics (CTMX) Stock a Solid Choice Right Now?

CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tirthankar Chakraborty

New Strong Buy Stocks for May 4th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Zacks Equity Research

CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?

CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why CytomX Therapeutics (CTMX) Stock Might be a Great Pick

CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Here's Why CytomX Therapeutics (CTMX) is a Great Momentum Stock to Buy

Does CytomX Therapeutics (CTMX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for April 17th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 17th

Zacks Equity Research

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's What You Should Know

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Will CytomX Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor CytomX Therapeutics

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for April 3rd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd

Zacks Equity Research

CytomX & Astellas Collaborate to Develop Novel Cancer Therapy

CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -43.64% and -47.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Will CytomX Therapeutics (CTMX) Report Negative Earnings Next Week? What You Should Know

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.36% and -40.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: CytomX Therapeutics (CTMX) Q2 Earnings Expected to Decline

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 41.51% and 116.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CytomX Therapeutics Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in CytomX Therapeutics.

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -26.19% and -23.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?